- Home
- PKBK vs RCKT Comparison
PKBK vs RCKT Comparison
Compare PKBK & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PKBK | RCKT |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | United States |
| Employees | 111 | 202 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.1M | 401.6M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | PKBK | RCKT |
|---|---|---|
| Price | $30.52 | $3.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $29.73 |
| AVG Volume (30 Days) | 65.2K | ★ 1.8M |
| Earning Date | 04-17-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | ★ 39.21 | N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $64.28 |
| P/E Ratio | $30.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.78 | $2.19 |
| 52 Week High | $31.45 | $6.89 |
Technical Indicators
Market Signals| Indicator | PKBK | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 58.32 | 33.23 |
| Support Level | $26.56 | $2.95 |
| Resistance Level | $31.35 | $3.52 |
| Average True Range (ATR) | 0.56 | 0.23 |
| MACD | -0.10 | -0.03 |
| Stochastic Oscillator | 49.50 | 10.36 |
Price Performance
Historical ComparisonAbout PKBK Parke Bancorp Inc.
Parke Bancorp Inc operates as a commercial bank providing personal and financial services to individuals and small to mid-sized businesses in various states of the USA. The bank offers services such as loan products, deposit services, and other financial products through its retail branches and other channels to its customers. Its lending businesses are commercial real estate lending, residential real estate lending, and construction lending, among others. The company operates one reportable segment of business, community banking.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.